



Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting

October 9, 2014

MENLO PARK, Calif., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting on Thursday, October 16, 2014 at 8:49 am CDT in Chicago, IL. Additionally, Dr. Chalberg will participate in the "IPOs in Ophthalmology – The Class of 2014 and Beyond" at 4:10 pm CDT.

About Avalanche Biotechnologies, Inc.

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit www.avalanchebiotech.com.

CONTACT: Investor Contact:

Chris Erdman
MacDougall Biomedical Communications
(781) 235-3060
cerdman@macbiocom.com

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.